Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Shares Outstanding (2016 - 2025)

Kiora Pharmaceuticals' Shares Outstanding history spans 11 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 25.36% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 25.36%, while the annual FY2025 figure was $3.8 million, 25.36% up from the prior year.
  • Shares Outstanding reached $3.8 million in Q4 2025 per KPRX's latest filing, up from $3.4 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $7.1 million in Q1 2021 to a low of $7.0 in Q2 2022.
  • Average Shares Outstanding over 5 years is $1.5 million, with a median of $316599.0 recorded in 2021.
  • Peak YoY movement for Shares Outstanding: soared 702660.66% in 2024, then plummeted 99.99% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $316599.0 in 2021, then surged by 240.82% to $1.1 million in 2022, then tumbled by 99.96% to $427.0 in 2023, then skyrocketed by 702660.66% to $3.0 million in 2024, then rose by 25.36% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Shares Outstanding are $3.8 million (Q4 2025), $427.0 (Q3 2025), and $427.0 (Q2 2025).